These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Clinical and immunological follow-up of B-cell depleting therapy in CNS demyelinating diseases.
    Author: Gredler V, Mader S, Schanda K, Hegen H, Di Pauli F, Kuenz B, Deisenhammer F, Berger T, Reindl M, Lutterotti A.
    Journal: J Neurol Sci; 2013 May 15; 328(1-2):77-82. PubMed ID: 23522498.
    Abstract:
    The aim of this observational study was to analyze clinical and immunological effects of rituximab treatment in neuromyelitis optica (NMO) and longitudinally extensive transverse myelitis (LETM) patients. We report on four NMO and two recurrent LETM patients who were treated with rituximab. Overall, B-cell depletion resulted in profound clinical stabilization in all patients. Rituximab did not affect titers of antibodies to aquaporin-4 (AQP4-IgG) and myelin oligodendrocyte glycoprotein, immunoglobulin (Ig) isotypes and IgG subtype distribution, even after long-term B-cell depletion. Relapses were not associated with re-emerging B-cells, serum levels of B-cell activating factor (BAFF) or AQP4-IgG titers. BAFF serum levels increased following rituximab treatment.
    [Abstract] [Full Text] [Related] [New Search]